Triple-digit CAGR pharma player hits the market: Should you invest? Triple-digit CAGR pharma player hits the market: Should you invest? Between FY22 and FY24, the company recorded a Compound Annual Growth Rate (CAGR) of around 285 per cent in revenue and 472 per cent in net profit. Mandar Wagh / Friday, December 20, 2024 0 277 Article rating: 5.0 Between FY22 and FY24, the company recorded a Compound Annual Growth Rate (CAGR) of around 285 per cent in revenue and 472 per cent in net profit. Read more